Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer

Vincenzo Valentini, Francesco Deodato, Francesco Cellini, Eleonora Farina, Jenny Capuccini, Luciana Caravatta, Nam P. Nguyen, Silvia Cammelli, Andrea Farioli, Giuseppe Zanirato Rambaldi, Tigeneh Wondemagegnhu, A.F.M. Kamal Uddin, Mostafà Aziz Sumon, Domenico Genovesi, Milly Buwenge, Alessio G. Morganti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

Aim: To determine the maximum tolerated dose (MTD) of a short-course accelerated radiotherapy and its feasibility for symptomatic palliation of advanced head and neck cancer or head and neck metastases from any primary site. Patients and Methods: A phase I trial in four dose-escalation steps was planned: total dose ranged between 14 and 20 Gy in a total of four fractions administered twice a day. The dose-limiting toxicity (DLT) was determined as grade 3 or more toxicity occurring during treatment. The MTD obtained was used to plan a phase II trial. Results: A total of 48 patients were treated. In the phase I trial, the 20 Gy dose level was determined to be the MTD. In the phase II trial, the palliative response rate was 82.7%, with a median duration of palliation of 3 months. Conclusion: Short-course accelerated radiotherapy was well tolerated and effective for palliation. These findings may help design future prospective randomized studies.
Lingua originaleEnglish
pagine (da-a)2409-2414
Numero di pagine6
RivistaAnticancer Research
Volume38
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell
  • Dose Fractionation, Radiation
  • Female
  • Head
  • Head and Neck Neoplasms
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Neck cancer
  • Pain
  • Palliative Care
  • Palliative care
  • Quality of Life
  • Quality of life
  • Radiotherapy
  • Radiotherapy Dosage
  • Time Factors

Fingerprint Entra nei temi di ricerca di 'Phase I-II study of short-course accelerated radiotherapy (SHARON) for palliation in head and neck cancer'. Insieme formano una fingerprint unica.

Cita questo